Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

111.94 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
63 64 Next >
What's Going On With Ginkgo Bioworks Stock?
Ginkgo Bioworks announced the expansion of its strategic partnership with Novo Nordisk A/S on Wednesday under a framework agreement that initially is contemplated to run over five years.Ginkgo said the... 
Via Benzinga
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks
These stocks to buy have enjoyed big rallies and the gains look likely to continue in coming months even if the market does peak. 
Via InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments 
Via InvestorPlace
2 Healthcare Stocks to Buy Hand Over Fist in April
Don't wait too long to invest in these exciting stocks. 
Via The Motley Fool
Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development
It may not be too late to invest in this promising healthcare stock, even though it may look expensive. 
Via The Motley Fool
Check Out What Whales Are Doing With NVO
Via Benzinga
Is NYSE:NVO a Good Fit for Dividend Investing?
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a good dividend investing stock. 
Via Chartmill
Assessing Novo Nordisk: Insights From 10 Financial Analysts
Via Benzinga
Smart Money Is Betting Big In NVO Options
Via Benzinga
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
Via MarketBeat
Exposures Product Safety
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend 
Via MarketBeat
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Shares of the clinical-stage biotech have skyrocketed on recent good news. 
Via The Motley Fool
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
New findings could lead to more growth from their prized medicines. 
Via The Motley Fool
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
With risk-on sentiment in place, investors may be looking for the most undervalued Russell 2000 stocks to buy in April. 
Via InvestorPlace
After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves
Novo Nordisk is off to a red-hot start in 2024, and its latest deal could represent huge potential. 
Via The Motley Fool
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
Viking shares have soared recently on optimism about its program. 
Via The Motley Fool
Why Eli Lilly Stock Topped the Market Today
One analyst following the company believes it could grow its revenue meaningfully this year. 
Via The Motley Fool
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy
Eli Lilly's stock skyrockets but now trading sideways as demand for weight-loss drugs outpaces supply. Availability issues lead to FDA shortages. 
Via Benzinga
Exposures Product Safety
Novo Nordisk's Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China
Novo Nordisk warns of Ozempic starter kit scarcity in Germany amid ongoing supply challenges in Europe. Restrictions on off-label use emphasized, with intermittent shortages expected in 2024.... 
Via Benzinga
Exposures Product Safety
Hedge Fund Favorites: 3 European Stocks Attracting Significant U.S. Investment
Investors looking for diversification should consider these European names that are increasingly popular among hedge fund managers. 
Via InvestorPlace
Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher 
Via MarketBeat
Exposures Product Safety
Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras
Costco's new weight loss initiative, in partnership with Sesame, a healthcare marketplace, will offer members a three-month clinical consultation and other services for $179. 
Via Benzinga
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over... 
Via Benzinga
Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand
Citi Research raises price target for Eli Lilly, citing improved risk-adjusted sales outlook for GLP-1 agonist orforglipron. With Phase 3 trials ongoing since 2023, concerns about liver toxicity... 
Via Benzinga
Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience
Eli Lilly's stock has performed well over the past year, gaining 116.84%. So far in 2024, the stock has returned 29.45% to investors. 
Via Benzinga
Diabetes Drug Made For Under $5 Costs Americans $1,000, Drawing Comparisons To Martin Shrikeli While Juicing Profits for A Drug Giant
Via Benzinga
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People 
Via MarketBeat
Could Viking Therapeutics Stock Be a Millionaire Maker?
There is a plausible path for this biotech stock to make some investors millionaires. 
Via The Motley Fool
Is It Too Late to Buy Eli Lilly Stock?
There's more to the Lilly story than just excellence in one treatment area. 
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
63 64 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.